Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.245 CAD | +2.08% | 0.00% | -15.52% |
01-16 | Vext Science, Inc. Announces Transition of Jason Thai Nguyen Out of Executive Role | CI |
2023 | Vext Science, Inc. Announces Board Changes | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- One of the major weak points of the company is its financial situation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.52% | 43.03M | - | ||
+27.84% | 272M | - | ||
+37.45% | 261M | - | ||
+47.09% | 194M | C | ||
+43.15% | 131M | - | ||
-28.57% | 121M | - | - | |
+115.91% | 119M | - | - | |
-37.75% | 119M | C | ||
+3.85% | 86.82M | - | - | |
+150.00% | 75.33M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- VEXT Stock
- Ratings Vext Science, Inc.